权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Commercial Readiness for Direct-to-Digital Pathology

直接数字病理学的商业准备

基本信息

批准号：
10678409
负责人：
Michael John Levene
金额：
$ 22.49万
依托单位：
APPLIKATE TECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-19 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10678409
关键词：
3-Dimensional Address Adult Anxiety Authorization documentation Biopsy Client Clinical Consultations Contracts Country Data Development Devices Diagnosis Diagnostic Diagnostic Errors Documentation Engineering Equipment Equipment and Supplies Evaluation Failure Feedback Funding General Practitioners Health Sciences Hearing Hematoxylin and Eosin Staining Method Histology Hospitals Hour Human Image Imaging Device Immunohistochemistry Instruction Laboratories Malignant Neoplasms Manufacturer Marketing Molecular Analysis Morphologic artifacts Noise Output Pathologic Pathologist Pathology Patient Care Patients Phase Preparation Privatization Procedures Prostatic Neoplasms Qualifying Readiness Recording of previous events Records Remote Consultation Research Research Contracts Research Design Resolution Risk Risk Management Savings Scanning Signal Transduction Slice Slide Small Business Innovation Research Grant Specimen System Technology Testing Thick Tissue imaging Tissues Translating United States National Institutes of Health Validation Wait Time Waxes Work Workload authority breast cancer diagnosis cancer diagnosis cancer subtypes clinical development clinical diagnostics cost design digital imaging digital pathology digital platform experience falls health economics imaging platform improved interest machine vision malignant breast neoplasm manufacture medical schools multiphoton microscopy novel preservation pressure prospective response stem submicron tissue processing verification and validation whole slide imaging

项目摘要

Project Summary Applikate Technologies has developed Clearing Histology with Multiphoton Microscopy (CHiMP), a novel tissue processing and imaging platform that provides direct-to-digital images from intact pathology tissue specimens, such as biopsies, without the need for wax embedding, slicing, or scanning of slides. The application of this technology to cancer diagnosis will reduce errors, lower costs, ameliorate technician staffing issues, and provide same-day diagnosis for patients waiting to hear if they have cancer. The aim of this Phase IIb SBIR proposal is to support the development of risk management and quality systems management required for the manufacture of clinical devices, as well as the clinical and non-clinical validation testing required for an application for premarket approval by the FDA. CHiMP has many advantages for general histology, including: H&E-like images familiar to pathologists but with superior image quality, sub-micron effective thickness, and without artifacts common to slide preparation; non- destructive imaging that preserves intact tissue for ancillary molecular analysis and immunohistochemistry; rapid turnaround, with images ready within a few hours of receiving tissue; greatly reduced labor costs; true 3D prospective; and digitized images for remote consultation and machine vision. The market for pathology equipment and consumables is $2B, and for digital pathology scanners it is $1B. CHiMP is poised to not only enter these markets as a unique and strong competitor, but to actually expand upon them by lowering the barrier to entry for digital pathology through seamless integration into the laboratory workflow and raising the value of equipment and supplies while still lowering overall costs to hospitals through significant labor savings. The specific aims of this proposal are to: 1) Perform risk analysis; 2)Develop and implement a Quality Management System; 3) Collect data for an FDA premarket submission and facility registration. Successful completion of these aims will enable CHiMP to enter the clinical diagnostic market, where it can have maximum impact on patient care and health economics.

项目总结